Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Enasidenib Sprinkle vs Tablet Formulation
NCT04310527Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Oct 2019
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of enasidenib in acute myeloid leukemia (AML) (3 arms), sponsored by Celgene Corporation. Primary endpoints: Maximum Plasma Concentration up to 14 days, Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity up to 14 days and 5 more. Started Oct 2019; status: completed.
02
Drugs
enasidenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04310527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04310527.